Allergan's Restasis Patents Are Valid, Fed. Circ. Told

Law360, San Francisco (January 10, 2018, 8:55 PM EST) -- The Saint Regis Mohawk Tribe, which acquired Allergan Inc.'s patents on the dry-eye drug Restasis, urged the Federal Circuit on Tuesday to reverse a ruling that invalidated four of its Restasis patents as obvious, arguing that the lower court's decision to ax the patents is “fraught with legal error.”

In their opening brief, the tribe and drugmaker argued that the lower court’s decision to invalidate the patents is not supported by the law, and it "substitutes statistical analysis for common sense." They said the ruling raises a nearly impossible barrier for pharmaceutical companies by requiring them to show that their claimed...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS